Global Diabetic Neuropathic Pain Market Report to 2031: Players Include AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and GlaxoSmithKline - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Diabetic Neuropathic Pain Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic neuropathic pain market through 2031.

Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.

Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs

Companies Mentioned

• AstraZeneca
• Boehringer Ingelheim
• Daiichi Sankyo Co
• Eli Lilly
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Grunenthal
• Helixmith Co
• Lexicon Pharmaceuticals
• Mitsubishi Tanabe Pharma Corp
• Mundipharma
• Novaremed AG
• Novartis
• Ono Pharmaceutical Co
• Pfizer
• Regenacy Pharmaceuticals
• Sun Pharmaceutical Industries
• UCB
• Viatris

Key Highlights

• Forecasts includes the 7MM
• Forecasts covers from 2021-2031
• In the 7MM, the diagnosed prevalent cases of DNP will increase from 4,447,050 cases in 2021 to 5,157,455 cases in 2031, at an AGR of 1.60%.
• The current DNP treatment landscape includes many established analgesics that provide symptomatic relief. The main drug classes that are used l include tricyclic antidepressants (TCAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), alpha-2-delta ligands (gabapentinoids), sodium channel blockers, and topical treatments.
• The DNP market will exhibit moderate growth between 2021 and 2031, driven by the entry of four pipeline agents.
• Engensis will be welcomed by patients as the underlying pathophysiology of DNP will be targeted, rather than symptomatic treatment.

Scope

• Overview of diabetic neuropathic pain, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for diabetic neuropathic pain treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathic pain therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global diabetic neuropathic pain therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Key Topics Covered:

1 Diabetic Neuropathic Pain: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Total prevalent cases of DNP

4.4.4 Diagnosed prevalent cases of DNP

4.4.5 Diagnosed prevalent cases of DNP by DSPN and non-DSPN

4.4.6 p-DPN among diagnosed prevalent cases of T1D and T2D

4.5 Epidemiological forecast for total prevalent cases of DNP (2021-31)

4.5.1 Total prevalent cases of DNP

4.5.2 Age-specific total prevalent cases of DNP

4.5.3 Sex-specific total prevalent cases of DNP

4.5.4 Diagnosed prevalent cases of DNP

4.5.5 Diagnosed prevalent cases of DNP by DSPN and Non-DSPN

4.5.6 p-DPN among diagnosed prevalent cases of T1D and T2D

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis overview

5.2 Treatment overview

5.3 Other KOL insights on disease management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Development of therapies with an improved efficacy profile

7.3 Development of therapies with improved safety and tolerability profile

7.4 Development of a curative or disease-modifying agent

7.5 Improving physician and public recognition of DNP

8 R&D Strategies

8.1 Overview

8.1.1 Development of analgesics with novel MOAs

8.1.2 Patient stratification

8.2 Clinical trials design

8.2.1 Clinical endpoints

8.2.2 High failure rate in DNP clinical trials

8.2.3 Patient recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

13 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y76znp

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900